Aquaro Histology is a technology company.
Aquaro Histology has raised $10.0M across 1 funding round.
Aquaro Histology has raised $10.0M in total across 1 funding round.
Aquaro Histology is a biotechnology startup founded in 2013 in Ann Arbor, Michigan, specializing in automated solutions for histology laboratory workflows.[1][2][3][4] The company develops, manufactures, and sells innovative devices that streamline critical processes like microtomy, improving efficiency, quality, and consistency for histology labs.[1][2][4][5] It targets pathology labs and research facilities facing manual, error-prone tissue processing, with reported revenue of $1.6 million and a small team of about 2 employees, plus financing secured for commercialization.[3][4]
Aquaro Histology was founded in 2013 by Vincent A. Alessi and Nolan Orfield, who identified inefficiencies in traditional histology lab procedures.[1] Based in Ann Arbor, MI, the company emerged from a focus on automating key steps in tissue sample preparation, such as microtomy—a pivotal process in pathology diagnostics.[1][4] Early milestones include completing financing to support commercialization of their automated microtomy technology, marking a shift from development to market entry.[4]
Aquaro Histology stands out in the histology automation space through:
Aquaro Histology rides the wave of lab automation and precision pathology, driven by rising demand for faster diagnostics amid growing cancer rates and personalized medicine trends.[1][5] Timing aligns with advances in AI-assisted pathology and biotech digitization, where manual histology bottlenecks hinder scalability—market forces like labor shortages and regulatory pushes for reproducibility favor automated solutions.[2][4] By influencing histology efficiency, Aquaro contributes to the broader ecosystem of diagnostic tech, enabling quicker tissue analysis for research and clinical use without disrupting established lab setups.[3][5]
Aquaro Histology is poised for growth through expanded commercialization of its microtomy tech, potentially capturing share in the $5B+ global histology market amid automation surges.[4] Trends like AI integration in pathology and rising lab throughput needs will shape its path, with partnerships or acquisitions by larger medtech firms likely amplifying influence. As a streamlined player solving real lab pain points, it exemplifies how targeted biotech innovation accelerates diagnostics—watch for revenue scaling and new product launches to solidify its niche.
Aquaro Histology has raised $10.0M in total across 1 funding round.
Aquaro Histology's investors include Telegraph Hill Partners.
Aquaro Histology has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Series A in November 2017.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2017 | $10.0M Series A | Telegraph Hill Partners |